Summary
Signal counts
Assets tracked: 2
Watchlist assets: 2
Registry stop assets: 2
Sponsor overview
UNC Lineberger Comprehensive Cancer Center
Public clinical-program risk signals across linked oncology Phase 2 assets for this sponsor.
Evidence links
Public sources
https://clinicaltrials.gov/study/NCT00283244 | https://clinicaltrials.gov/study/NCT01259089 | https://clinicaltrials.gov/study/NCT00573989 | https://clinicaltrials.gov/study/NCT00087269 | https://clinicaltrials.gov/study/NCT00754494 | https://clinicaltrials.gov/study/NCT00088985 | https://clinicaltrials.gov/study/NCT00499083
Assets
Linked programs
- erlotinib hydrochloride: Registry Stop Signal (4/5)
- therapeutic autologous dendritic cells: Registry Stop Signal (4/5)